<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124444</url>
  </required_header>
  <id_info>
    <org_study_id>2015/379</org_study_id>
    <nct_id>NCT05124444</nct_id>
  </id_info>
  <brief_title>TOlerance MOlecular and Genome-wide Studies With Renal Allograft Recipient Material</brief_title>
  <acronym>TOMOGRAM</acronym>
  <official_title>TOlerance MOlecular and Genome-wide Studies With Renal Allograft Recipient Material</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Libre de Bruxelles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DESCARTES Working Group On Transplantation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université Libre de Bruxelles</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TOMOGRAM is a European multicentric, prospective, experimental, controlled study that aims to&#xD;
      increase our understanding of the causative mechanisms of operational tolerance in kidney&#xD;
      transplantation through the achievement of several multimodal whole-genomic analysis in human&#xD;
      biological samples.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2015</start_date>
  <completion_date type="Actual">September 29, 2021</completion_date>
  <primary_completion_date type="Actual">October 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Exome-wide association study&#xD;
Transcriptomic analyses</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of moderately to highly damaging exonic variants</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Cases (tolerant patients)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>High throughput DNA and RNA sequencing</intervention_name>
    <description>High throughput DNA and RNA sequencing</description>
    <arm_group_label>Cases (tolerant patients)</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  recipient of an allogenic renal allograft,&#xD;
&#xD;
          -  have experienced (whatever ongoing or not) at least a whole year with blood creatinine&#xD;
             &lt;1.7 mg/dL and proteinuria &lt;/=1g/day or /g creatinine despite the COMPLETE&#xD;
             discontinuation of immunosuppressive drugs,&#xD;
&#xD;
          -  alternatively, have experienced (whatever ongoing or not) at least a whole year with&#xD;
             stable blood creatinine (max 20% variation) and proteinuria above these criteria&#xD;
             despite the COMPLETE discontinuation of immunosuppressive drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past medical history of allogeneic bone-marrow transplantation / combined organ&#xD;
             transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université Libre de Bruxelles</investigator_affiliation>
    <investigator_full_name>Annick Massart</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

